Clinical trials: Frown Lines
Frown Lines
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.
- Trial name
- H2H (NCT04763265)
- Testing
- Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 208 people
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening.
- Trial name
- NCT00430963
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- Germany
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.
- Trial name
- NCT05481931
- Testing
- prabotulinumtoxinA
- Where
- Germany
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Longitudinal Evaluation and Real-world Evidence of NT201
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A…
- Trial name
- NCT05222607
- Testing
- IncobotulinumtoxinA
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
- Trial name
- NCT05217355
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Medytox Korea
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014622
- Testing
- Botulinum Toxins, Type A
- Where
- 15 sites in United States
- Volunteers
- 303 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum…
- Trial name
- STAR (NCT05277337)
- Testing
- Alluzience, powder BoNT-A (BOTOX/Vistabel)
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Galderma R&D
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01224015
- Testing
- normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- Allergan
Glabellar Frown Lines
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.
- Trial name
- NCT05059587
- Testing
- MBA-P01, BOTOX
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Medytox Korea
Glabellar Rhytides
A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the long-term safety of repeat treatment with an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines.
- Trial name
- PT-03c (NCT00752258)
- Testing
- Mentor Purified Toxin Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 576 people
- Sponsor
- Mentor Worldwide, LLC
Glabellar Frown Lines, Canthal Lines
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
This study to assess aesthetic improvement following treatment with QM1114-DP.
- Trial name
- NCT05148000
- Testing
- QM1114-DP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA II (NCT04622254)
- Testing
- NT 201
- Where
- 12 sites in Germany
- Volunteers
- 368 people
- Sponsor
- Merz North America, Inc.
Glabellar Lines, Glabellar Frown Lines
A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
The aim of this study is to evaluate the efficacy and safety of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) for correction of moderate to severe glabellar lines.
- Trial name
- NCT06946160
- Testing
- Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.)
- Where
- Iran
- Volunteers
- 146 people
- Sponsor
- Espad Pharmed
Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines…
- Trial name
- NCT01485601
- Testing
- MT10109
- Where
- Australia
- Volunteers
- 121 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Moderate to Severe Glabellar Frown Lines
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines (GFL).
- Trial name
- NCT03806933
- Testing
- NT 201
- Where
- 9 sites in United States, Germany
- Volunteers
- 241 people
- Sponsor
- Merz Aesthetics GmbH
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT04281745
- Testing
- CORETOX Inj
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines
This study evaluates the long-term safety of repeated administrations of Meditoxin® in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT03289169
- Testing
- MEDITOXIN®
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line
This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.
- Trial name
- NCT03908008
- Testing
- Botox (Botulinum toxin type A), MT10107 (Botulinum toxin type A)
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Medy-Tox